Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives
This article summarizes the barriers limiting the use of rituximab, and discusses the effectiveness and safety of current and fledgling treatment options.
Authors
- Lingxiao Pan (ORCID: https://orcid.org/0000-0001-6799-1855)
- Jianfeng Zhu (ORCID: https://orcid.org/0000-0002-4453-611X)
Institutions
- Nantong University (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
Publication Details
- Journal
- Current Opinion in Hematology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1097/moh.0000000000000902
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00